Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICT-107 with Maintenance TMZ in Newly Diagnosed Glioblastoma
NCT02546102Phase 3Suspended
- Sponsor
- Precision Lifesciences Group
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 3
01
Overview
A Phase 3 trial of ict-107 in glioblastoma multiforme (GBM), sponsored by Precision Lifesciences Group. Started Dec 2024; status: suspended.
02
Drugs
ict-107
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02546102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546102.